Literature DB >> 7647018

Excessive bone resorption in human plasmacytomas: direct induction by tumour cells in vivo.

R Bataille1, D Chappard, M Basle.   

Abstract

We studied the bone resorption (BR) in 82 patients with overt plasmacytomas (PCT) by histomorphometry. All the solitary PCT and 90% of overt PCT in complete remission lacked excessive BR. In contrast, 73% of the 68 patients with active overt PCT had an excessive BR. This excessive BR was highly related to the presence of tumour cells within the bone sample. Indeed, 92% of patients with active PCT and tumour cells within the biopsy had an excessive BR. On the other hand, 70% of patients with active PCT but lacking tumour cells within the biopsy had normal BR.

Entities:  

Mesh:

Year:  1995        PMID: 7647018     DOI: 10.1111/j.1365-2141.1995.tb05609.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

Review 1.  Bone disease from monoclonal gammopathy of undetermined significance to multiple myeloma: pathogenesis, interventions, and future opportunities.

Authors:  Alex R Minter; Haley Simpson; Brendan M Weiss; Ola Landgren
Journal:  Semin Hematol       Date:  2011-01       Impact factor: 3.851

Review 2.  Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management.

Authors:  Sigurdur Y Kristinsson; Alex R Minter; Neha Korde; Esther Tan; Ola Landgren
Journal:  Expert Rev Mol Diagn       Date:  2011-07       Impact factor: 5.225

3.  Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation.

Authors:  Scott A Ely; Daniel M Knowles
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

4.  Severe hypercalcaemia and extensive osteolytic lesions in an adult patient with T cell acute lymphoblastic leukaemia.

Authors:  P Antunovic; D Marisavljevic; N Kraguljac; V Jelusic
Journal:  Med Oncol       Date:  1998-04       Impact factor: 3.064

Review 5.  Cancer-associated bone disease.

Authors:  R Rizzoli; J-J Body; M-L Brandi; J Cannata-Andia; D Chappard; A El Maghraoui; C C Glüer; D Kendler; N Napoli; A Papaioannou; D D Pierroz; M Rahme; C H Van Poznak; T J de Villiers; G El Hajj Fuleihan
Journal:  Osteoporos Int       Date:  2013-10-22       Impact factor: 4.507

6.  Quantification of dendritic cells and osteoclasts in the bone marrow of patients with monoclonal gammopathy.

Authors:  Nicolas Josselin; Hélène Libouban; Mamoun Dib; Norbert Ifrah; Erick Legrand; Michel Félix Baslé; Maurice Audran; Daniel Chappard
Journal:  Pathol Oncol Res       Date:  2008-08-28       Impact factor: 3.201

7.  Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options.

Authors:  Güven Çetin; Ahmet Emre Eşkazan; M Cem Ar; Şeniz Öngören Aydın; Burhan Ferhanoğlu; Teoman Soysal; Zafer Başlar; Yıldız Aydın
Journal:  Turk J Haematol       Date:  2014-12-05       Impact factor: 1.831

Review 8.  Role of osteocytes in multiple myeloma bone disease.

Authors:  Jesus Delgado-Calle; Teresita Bellido; G David Roodman
Journal:  Curr Opin Support Palliat Care       Date:  2014-12       Impact factor: 2.302

Review 9.  Bone disease in myeloma.

Authors:  J R Berenson
Journal:  Curr Treat Options Oncol       Date:  2001-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.